Viromed Medical AG has successfully completed the capital increase it announced, placing 450,000 new registered no-par value shares at a placement price of EUR 4.50 per share. According to the company announcement carried by NEWMEDIAWIRE, the gross proceeds amount to approximately EUR 2 million and will be used to finance the company's working capital.
Subject to registration of the implementation of the capital increase in the commercial register, the share capital will rise from EUR 21,250,000 by EUR 450,000 to EUR 21,700,000. The capital increase was carried out by partially utilizing the Authorized Capital 2025 and with the exclusion of the shareholders' subscription rights, meaning existing shareholders did not receive a pre-emptive right to subscribe to the new shares.
The transaction matters for investors and the wider medical technology sector because it gives the company fresh cash without a lengthy public offering process, but it also dilutes existing holders, who were unable to participate. The exclusion of subscription rights concentrates the new shares among the placement recipients, a structure that can invite scrutiny from shareholders focused on governance and the terms of the placement.
Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond, and it is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.
The roughly EUR 2 million in gross proceeds is modest in absolute terms, but for a small-cap medical technology issuer it represents meaningful working capital that could support inventory, distribution and commercialization efforts around cold plasma applications. The capital increase follows a path already announced by the company, and further details are available in the original release on www.newmediawire.com.
For readers following the cold plasma segment, the key takeaway is that Viromed is funding its near-term operations through equity rather than debt, a choice that preserves balance-sheet flexibility but transfers a slice of ownership to new shareholders. The completion of the placement, pending commercial register registration, marks a concrete step in the company's stated ambition to expand the medical use of cold plasma technology across the DACH region and beyond.
